SCHEMBL21362034

SCHEMBL21362034

Cn1cc(-c2cc(NC(=O)OC(C)(C)C)ccc2C(=O)c2ccc(Cl)cc2)c(CNC(=O)OC(C)(C)C)cc1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.38
BRAF P15056 1/20 0.38
BRD4 O60885 3/20 0.36
RORC P51449 1/20 0.35
HDAC6 Q9UBN7 2/20 0.35
ACHE P22303 1/20 0.35
BACE1 P56817 1/20 0.35
HDAC10 Q969S8 1/20 0.35
DRD2 P14416 2/20 0.35
F11 P03951 1/20 0.34
PTGES O14684 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
GAA P10253 1/20 0.34
KCNA5 P22460 1/20 0.34
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
HDAC1 Q13547 1/20 0.34
MAPK8 P45983 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20157758 0.91 RAF1 (0.40) RAF1BRAFBRD4RORCACHE
SCHEMBL20157810 0.88 BRD4 (0.46) BRD4HDAC6HDAC10DRD2GAA
SCHEMBL21352057 0.85 BRD4 (0.34) BRD4HDAC6ACHEHDAC10DRD2
SCHEMBL20157351 0.84 HDAC10 (0.36) BRD4HDAC6HDAC10DRD2GAA
SCHEMBL20157838 0.81 RAF1 (0.36) RAF1BRAFBRD4HDAC6HDAC10
SCHEMBL20157374 0.79 EPHX2 (0.41) BRD4GAA
SCHEMBL21362132 0.79 BRD4 (0.34) BRD4HDAC6HDAC10DRD2PRMT5
SCHEMBL21362397 0.79 PPARG (0.35) BRD4PRMT5WDR77PPARGPPARA
SCHEMBL21351986 0.78 BRD4 (0.36) BRD4RORCGAA
SCHEMBL20157348 0.77 HDAC10 (0.35) RAF1BRAFBRD4HDAC6HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 RAF1 437/4885BRAF 313/4885BRD4 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.